Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Tetra Therapeutics patents

List of Tetra Therapeutics patents

List of Henan Polytechnic University patents

List of Bottomline Technologies patents

List of Life Fitness patents

Homomorphic encryption venture capital investors

List of funding rounds for Crescendo Bioscience

Patents where

Current Assignee

Name

is

Tetra Therapeutics

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11401286 Heteroaryl inhibitors of PDE4	Patent 11401286 was granted and assigned to Tetra Therapeutics on August, 2022 by the United States Patent and Trademark Office.	Tetra Therapeutics	Tetra Therapeutics		United States Patent and Trademark Office	11401286	August 2, 2022
	‌ US Patent 10364258 Heteroaryl inhibitors of PDE4	Patent 10364258 was granted and assigned to Tetra Therapeutics on July, 2019 by the United States Patent and Trademark Office.	Tetra Therapeutics	Tetra Therapeutics		United States Patent and Trademark Office	10364258	July 30, 2019
	‌ US Patent 10093686 Heteroaryl inhibitors of PDE4	Patent 10093686 was granted and assigned to Tetra Therapeutics on October, 2018 by the United States Patent and Trademark Office.	Tetra Therapeutics	Tetra Therapeutics		United States Patent and Trademark Office	10093686	October 9, 2018
	‌ US Patent 11028050 Salts and polymorphs of a PDE4 inhibitor	Patent 11028050 was granted and assigned to Tetra Therapeutics on June, 2021 by the United States Patent and Trademark Office.	Tetra Therapeutics	Tetra Therapeutics		United States Patent and Trademark Office	11028050	June 8, 2021
	‌ US Patent 9777024 Heteroaryl inhibitors of PDE4	Patent 9777024 was granted and assigned to Tetra Therapeutics on October, 2017 by the United States Patent and Trademark Office.	Tetra Therapeutics	Tetra Therapeutics		United States Patent and Trademark Office	9777024	October 3, 2017
	‌ US Patent 11104660 PDE4D inhibitors	Patent 11104660 was granted and assigned to Tetra Therapeutics on August, 2021 by the United States Patent and Trademark Office.	Tetra Therapeutics	Tetra Therapeutics		United States Patent and Trademark Office	11104660	August 31, 2021
	‌ US Patent 10626129 Heteroaryl inhibitors of PDE4	Patent 10626129 was granted and assigned to Tetra Therapeutics on April, 2020 by the United States Patent and Trademark Office.	Tetra Therapeutics	Tetra Therapeutics		United States Patent and Trademark Office	10626129	April 21, 2020
	‌ US Patent 9221843 Heteroaryl inhibitors of PDE4	Patent 9221843 was granted and assigned to Tetra Therapeutics on December, 2015 by the United States Patent and Trademark Office.	Tetra Therapeutics	Tetra Therapeutics		United States Patent and Trademark Office	9221843	December 29, 2015
	‌ US Patent 8865723 Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury	Patent 8865723 was granted and assigned to Tetra Therapeutics on October, 2014 by the United States Patent and Trademark Office.	Tetra Therapeutics	Tetra Therapeutics		United States Patent and Trademark Office	8865723	October 21, 2014

9 results

0 selected

9 results

0 selected